Showing 2311-2320 of 8080 results for "".
Journal Club: Dupilumab and Atopic March
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedFDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Nail Disease and JAK Inhibitor Safety
https://reachmd.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Rosacea Comorbidities and Skincare with Energy-Based Devices
https://reachmd.com/programs/practical-dermatology/rosacea-comorbidities-and-skincare-with-energy-based-devices/35895/Ted Lain, MD, MBA, discusses the gut-skin connection as it relates to rosacea, as well as skincare with energy-based devices, at Music City SCALE 2025.Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.Procedural Management for HS
https://reachmd.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fSunscreen as Self-Care
https://practicaldermatology.com/series/c-suite-chats/sunscreen-as-self-care/33249/Arielle Moody, product developer at Mama Sol, talks about the importance of sunscreen in beauty routines and how her company is attempting to make it more appealing.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeNovel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.